M&A Deal Summary

AstraZeneca Acquires Amolyt Pharma

On March 14, 2024, AstraZeneca acquired life science company Amolyt Pharma from Andera Partners and EQT Life Sciences for 1.1B USD

Acquisition Highlights
  • This is AstraZeneca’s 16th transaction in the Life Science sector.
  • This is AstraZeneca’s 11th largest (disclosed) transaction.
  • This is AstraZeneca’s 1st transaction in France.

M&A Deal Summary

Date 2024-03-14
Target Amolyt Pharma
Sector Life Science
Buyer(s) AstraZeneca
Sellers(s) Andera Partners
EQT Life Sciences
Deal Type Add-on Acquisition
Deal Value 1.1B USD

Target

Amolyt Pharma

Ecully, France
Amolyt Pharma is a clinical-stage biotechnology company, building therapeutic peptides to deliver life-changing treatments to patients suffering from rare endocrine and related diseases. Amolyt Pharma was founded in 2015 and is based in Ecully, France.

Search 200,500 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try For Free 7-Day Free Trial

Buyer(S) 1

Buyer

AstraZeneca

Cambridge, United Kingdom

Category Company
Founded 1992
Sector Life Science
Employees83,100
Revenue 45.8B USD (2023)
DESCRIPTION
Main office on AstraZeneca's campus in Waltham, Massachusetts.
Main office on AstraZeneca's campus in Waltham, Massachusetts.

AstraZeneca is a global biopharmaceutical company that focuses on the discovery, development, and commercialization of prescription medicines in several major disease areas, including oncology, cardiovascular, renal & metabolism, and respiratory & immunology. The Company's aim is to improve the health and quality of life of patients around the world through medicines, treatment solutions, and accessibility to healthcare. AstraZeneca is involved in both the research and development (R&D) and manufacturing of drugs to address critical areas of unmet medical need. AstraZeneca was founded in 1992 and is based in Cambridge, United Kingdom.


DEAL STATS #
Overall 18 of 19
Sector (Life Science) 16 of 17
Type (Add-on Acquisition) 14 of 15
Country (France) 1 of 1
Year (2024) 1 of 2
Size (of disclosed) 11 of 17
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2023-12-26 Gracell Biotechnologies

Suzhou, China

Gracell Biotechnologies is a global clinical-stage biopharmaceutical company dedicated to discovering and developing breakthrough cell therapies. Leveraging its pioneering FasTCAR and TruUCAR technology platforms, Gracell is developing a rich clinical-stage pipeline of multiple autologous and allogeneic product candidates with the potential to overcome major industry challenges that persist with conventional CAR-T therapies, including lengthy manufacturing time, suboptimal production quality, high therapy cost and lack of effective CAR-T therapies for solid tumors. Gracell Biotechnologies was founded in 2017 and is based in Suzhou, China.

Buy $1.2B
FOLLOWING DEAL
DATE TARGET DEAL TYPE VALUE
2024-03-19 Fusion Pharmaceuticals

Hamilton, Ontario, Canada

Fusion Pharmaceuticals is a pharmaceutical company focused on the targeted alpha therapy field. Fusion will exploit its unique expertise in linking medical isotopes to targeting molecules to create highly effective therapeutics. Fusion Pharmaceuticals was formed in 2014 and is based in Hamilton, Ontario.

Buy $2.4B

Seller(S) 2

SELLER

Andera Partners

Investor Investor Investor Investor


Category Private Equity Firm
Founded 2001
PE ASSETS 3.7B EUR
Size Large
Type Sector Agnostic
DESCRIPTION

Andera Partners is a private investment firm focused on several strategies. The Firm invests in life science opportunities through its BioDiscovery group. The Firm invests in Western European small to mid-sized companies (€30 to €300 million of revenue) through its Winch Capital group. Andera invests in small to mid-sized French companies (€10 to €100 million of revenue) through its Cabestan Capital team. Andera invests in €5 to €45 million of mezzanine capital to support small to mid-sized French companies. Andera Partners was established in 2001 and is headquartered in Paris.


DEAL STATS #
Overall 38 of 41
Sector (Life Science) 7 of 7
Type (Add-on Acquisition) 13 of 14
Country (France) 28 of 30
Year (2024) 1 of 4
Size (of disclosed) 2 of 3
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2024-03-06 Groupe ADF

Vitrolles, France

Groupe ADF is a provider of industrial engineering and maintenance services. Groupe ADF specialising in three business lines engineering & expertise, the supply of production and testing equipment, and production & maintenance services. Groupe ADF serves the Aeronautics, Space & Defense Industry, Energies, Oil & Gas sectors. Groupe ADF is based in Vitrolles, France.

Buy -
FOLLOWING DEAL
DATE TARGET DEAL TYPE VALUE
2024-07-24 JenaValve Technology

Irvine, California, United States

JenaValve Technology specializes in developing transcatheter aortic valves that can be implanted via the femoral vein or an incision between two ribs. JenaValve Technology was founded in 2006 and is based in Irvine, California.

Sell -
SELLER

EQT Life Sciences


Category Growth Capital Firm
Founded 1987
PE ASSETS 2.0B USD
Size Large
Type Sector Focused
DESCRIPTION


DEAL STATS #
Overall 4 of 7
Sector (Life Science) 2 of 3
Type (Add-on Acquisition) 3 of 6
Country (France) 1 of 1
Year (2024) 1 of 4
Size (of disclosed) 1 of 2
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2023-09-06 Atlantic Therapeutics

Galway, Ireland

Atlantic Therapeutics is a developer of professional and consumer medical devices, related software and connected health technologies. Atlantic Therapeutics with its product INNOVO focuses on the treatment of incontinence, sexual health dysfunctions and other associated disorders by strengthening the muscles and modulating the nerves of the pelvic floor. Atlantic Therapeutics was founded in 2017 and is based in Galway, Ireland.

Sell -
FOLLOWING DEAL
DATE TARGET DEAL TYPE VALUE
2024-03-25 Cardior

Hannover, Germany

Cardior is a clinical-stage biopharmaceutical company pioneering the discovery and development of RNA-based therapeutics designed to prevent, repair, and reverse diseases of the heart. The company's therapeutic approach uses distinctive non-coding RNAs as an innovative platform for addressing the root causes of cardiac dysfunctions. Cardior was founded in 2016 and is based in Hannover, Germany.

Sell $1.0B